Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]
It has never been filed for FDA evaluation in the United States, where it is not marketed.
References [edit]
- ^ Kitajima K, Adachi T, Takahashi I, et al. (November 1989). "[Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis]". Gan To Kagaku Ryoho (in Japanese) 16 (11): 3573–9. PMID 2817908.
- ^ Nagai M, Tasaka T, Kamano H, et al. (December 1988). "[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]". Gan To Kagaku Ryoho (in Japanese) 15 (12): 3267–70. PMID 3196045.
- (Japanese) Cymerin サイメリン (PDF) Mitsubishi Tanabe Pharma. October 2007.
(what is this?) (verify)
